Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.
The Hyderabad-based Hetero group, on June 27, announced the launch of its biosimilar bevacizumab (marketed as Cizumab) for the treatment of metastatic colorectal cancer (mCRC).
Cizumab is available as a single dose vial in two strengths - 100mg and 400mg - and has been priced...